Researchers have noted that people who regularly take anti-inflammatory medicines seem less likely to develop Alzheimer’s disease. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) is a clinical research study that is testing the link between the use of anti-inflammatory medicines and the prevention of Alzheimer’s disease. The study is sponsored by the National Institute on Aging, part of the National Institutes of Health.
Who is eligible to participate?
ADAPT participants must be age 70 or older, have a sibling or parent who has (or had) serious age-related memory loss, dementia, senility, or Alzheimer’s disease, and they must not have been diagnosed themselves with dementia or Alzheimer’s disease.
ADAPT is not currently recruiting new participants.
What happens at the visits?
Participants in ADAPT are asked to:
- take an anti-inflammatory medicine, either naproxen (Aleve) or celecoxib (Celebrex) or placebo (sugar pill) daily for several years*
- go to the local study site for a medical evaluation (cognitive and physical tests), 3 times in the first year of the study and twice a year after that
- participate in a telephone interview twice a year
* As of 12/17/04 ADAPT study medications have been suspended; participants are currently being followed off study medications. For more details, click here.
Where is the study taking place?
How can I find out more?
This study is no longer open to enrollment. For more information on how to participate in other studies, please call Erin Whalen at 617-414-1078.
Key Personnel?
|
